Bristol-Myers Squibb
BMY
2,189 hedge funds and large institutions have $98.8B invested in Bristol-Myers Squibb in 2020 Q2 according to their latest regulatory filings, with 158 funds opening new positions, 940 increasing their positions, 821 reducing their positions, and 99 closing their positions.
60% more first-time investments, than exits
New positions opened: 158 | Existing positions closed: 99
14% more repeat investments, than reductions
Existing positions increased: 940 | Existing positions reduced: 821
2% more funds holding
Funds holding: 2,148 → 2,189 (+41)
4% more capital invested
Capital invested by funds: $95.4B → $98.8B (+$3.37B)
9% less call options, than puts
Call options by funds: $1.44B | Put options by funds: $1.58B
1.38% less ownership
Funds ownership: 75.9% → 74.52% (-1.4%)
19% less funds holding in top 10
Funds holding in top 10: 135 → 110 (-25)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nordea Investment Management
Stockholm,
Sweden
|
+$578M |
| 2 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$322M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$298M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$281M |
| 5 |
JP Morgan Chase
New York
|
+$246M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$1.35B |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$709M |
| 3 |
Charles Schwab
San Francisco,
California
|
-$506M |
| 4 |
Dodge & Cox
San Francisco,
California
|
-$462M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$435M |
BMY Hedge Fund Activity: Q2 2020 in Review
2,189 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q2 2020, worth a combined $98.8B — up 3.5% from $95.4B a quarter earlier.
Buyers outnumbered sellers: 158 funds opened new BMY positions and 99 closed out — a net gain of 59 holders — while 940 added to existing stakes and 821 trimmed.
The largest buyer was Nordea Investment Management, adding an estimated $578M. The largest seller was Renaissance Technologies, cutting an estimated $1.35B.
- 2,189 institutional investors held Bristol-Myers Squibb (BMY) as of Q2 2020, up from 2,148 in Q1 2020.
- Funds reported $98.8B of Bristol-Myers Squibb stock for Q2 2020, up 3.5% quarter-over-quarter.
- 158 funds opened new Bristol-Myers Squibb positions in Q2 2020 and 99 closed out, a net change of +59 holders.
- The largest Bristol-Myers Squibb buyer in Q2 2020 was Nordea Investment Management, an estimated $578M added.
- The largest Bristol-Myers Squibb seller in Q2 2020 was Renaissance Technologies, an estimated $1.35B sold.
Based on aggregated 13F filings for Q2 2020.